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Abstract
Temporal lobe epilepsy (TLE) is the most common form of focal epilepsy, and
one that is generally amenable to surgical treatment when surgery is
necessary. Unfortunately, roughly 25-30% of the patient population have no
visible lesions on clinical MRI scans. Without anatomical abnormalities to
help guide surgical resection, the success of surgical treatment decreases
substantially. However, metabolic abnormalities may exist that could allow
for accurate localization of epileptic tissue in this cohort. Magnetic resonance
spectroscopy (MRS) is a technique that can detect and measure the
concentration of metabolically important molecules within tissue, giving
insight into the underlying cellular metabolism.
In this thesis, non-lesional TLE patients were studied and compared with
control subjects using single voxel MRS at a magnetic field strength of 7T for
the first time. We hypothesized that metabolite changes in the hippocampus
would be associated with seizure lateralization. Non-lesional patients showed
altered levels of creatine and choline when compared to healthy controls.
These results were in agreement with prior work in the literature showing
non-lesional TLE is primarily a result of glial cell proliferation without
neuronal atrophy. However, in the patient cohort studied, these metabolites
did not effectively lateralize seizure origin, potentially due to the varied
underlying pathologies within the patient group.
Keywords: Epilepsy, Temporal Lobe Epilepsy, Magnetic Resonance
Spectroscopy, Magnetic Resonance Imaging, 7T, Choline
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Chapter 1
Introduction

2
1.1

Research Motivation and Objectives

The motivation for the work presented in this thesis was to improve surgical
outcomes for patients with drug resistant temporal lobe epilepsy and normal
appearing clinical MRI scans. In drug resistant epilepsy, surgical removal of
seizure forming tissue is the most common method of treatment. However
localization of seizure focus is often difficult in patients without visible
disease markers on MRI, due to the poor localization abilities of other
techniques such as electroencephalography (EGG) and clinical semiology.
Uncertainty in the location of seizure origin has been shown to reduce the
success rate of epilepsy surgery, largely because some seizure forming tissue
can be missed in the resection. To address this issue, magnetic resonance
spectroscopy (MRS) was explored in this thesis as a technique to noninvasively identify and localize epileptic tissue in pre-surgical planning.
Metabolite changes measured by MRS are indicative of altered tissue
metabolism, and may be changed by seizure activity in the absence of MRI
visible lesions. These MRS measurements were performed in this patient
population for the first time at a magnetic field strength of 7T, with the goal
of demonstrating that additional information can be gleaned from these
measurements at 7T and to establish the clinical utility of the method.
1.2

Epilepsy

Epilepsy is described by the International League Against Epilepsy as, “… A
diverse family of disorders, having in common an abnormally increased
predisposition to seizures.” [1] Seizures themselves are transient events
where neurons within the cortex begin firing out of control in a highly
synchronous manner. The outward manifestations of a seizure vary
dramatically from patient to patient based on where in the brain a seizure
starts and how the seizure spreads throughout the cortex. These outward
manifestations include potential symptoms such as behavioural arrest, loss of
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consciousness, mood changes, and uncontrolled muscle contractions or
spasms. Seizures can have a particularly devastating effect on a patient’s
quality of life as loss of awareness and/or bodily control at unpredictable
times robs many patients of their ability to function independently [1].
Furthermore, epilepsy is associated with a wide range of long term effects
and comorbidities such as cognitive deficits (especially memory deficits) and
mood disorders such as depression [2], [3]. Those with epilepsy are also at a
significantly increased risk for sudden unexpected death (SUDEP) [4], and
they are at risk for developing status epilepticus; a condition where the
brain’s inhibitory mechanisms cannot bring a seizure under control, leading
to a prolonged seizure that can cause permanent brain damage or death [5].
From a clinical perspective, epilepsy is commonly divided into two subtypes,
focal and generalized epilepsy. Focal epilepsy describes a condition where a
patient’s seizures consistently arise from specific unilateral regions within
the brain, whereas generalized epilepsy describes patients where the seizure
onset involves activation of large regions in both hemispheres simultaneously
[6]. Within this classification scheme, temporal lobe epilepsy (TLE) is the
most common form of focal epilepsy [7]–[9].
1.2.1

The Temporal Lobe

The temporal lobe is one of the primary divisions of the cerebrum; it lies near
the base of the skull beneath the Sylvan fissure (Figure 1.1). The temporal
lobes are functionally important for their role in the consolidation of memory
and in forming speech. In the study of epilepsy, the mesial temporal lobe is
particularly important (Figure 1.2). This region consists of a folded grey
matter structure known as the hippocampus and nearby regions of cortical
grey matter within the hippocampal gyrus. It receives highly processed
sensory information from many disparate regions of the brain, and is
responsible for consolidating working memory into long-term declarative
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memory (facts and experiences). The mesial temporal lobe is the most
common site of origin for temporal lobe seizures. Hippocampal sclerosis
(hardening and atrophy of the hippocampus) has been the most common
cause of epilepsy in this patient group; over 57% of patients with drugresistant TLE have clear hippocampal sclerosis on MRI (Figure 1.3) [10]–[12].
1.2.2

Neurotransmission

To understand epilepsy and the pathophysiology involved, it is important to
understand the basic construction of the central nervous system (CNS). The
two primary cell types composing the CNS are neurons and glial cells [10].
1.2.2.1

Neurons

Neurons are the fundamental building blocks of the nervous system. A
neuron is composed of a main cell body with numerous branches of varying
lengths extending from this central core (Figure 1.4). Typically, a neuron will
have a single main branch extending off the cell body, termed the axon, and
numerous smaller branches, termed dendrites. Neurons receive a
combination of electrical and/or chemical signals through interfaces across its
surface called synapses, and transmit information away from the cell body
along the axon, which in turn is connected to other neurons. When describing
the transmission of signals between two neurons, a neuron that is sending
signals are often referred to as the pre-synaptic neuron, while the neuron
receiving signal from the pre-synaptic neuron is referred to as the postsynaptic neuron.
Neurons come in a wide range of shapes and sizes based on their function.
Neurons used to connect the central nervous system to distant anatomical
regions can be over a metre in length, while neurons within different parts of
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Figure 1.1 - Lobes of the Human Brain
Image by Henry Vandyke Carter and Henry Gray [13] [Public Domain], accessed via
Wikimedia Commons

Figure 1.2 - Anatomy of the Mesial Temporal Lobe
Image by Dr. Johannes Sobotta [14] [Public Domain], accessed via Wikimedia Commons

6

Figure 1.3 – T1- and T2-weighted Images of Hippocampal Sclerosis: Image showing T2weighted (A) and T1-weighted (B) images of an epileptic patient with unilateral right
hippocampal sclerosis (arrow). Note the increase in T2 signal, tissue atrophy, and loss of
internal structure in the sclerotic hippocampus as compared to the healthy contralateral
hippocampus.
Image by K. Ganesan and M. Ursekar [15], [Licensed for non-commercial use under CC-BYNC-SA 3.0 (https://creativecommons.org/licenses/by-nc-sa/3.0/)], accessed via the Indian
Journal of Radiology and Imaging
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Figure 1.4 - Labeled Diagram of
a Neuron
Image by Nicholas Rougier
[Licensed under CC-BY-SA 3.0
(http://creativecommons.org/licenses/
by-sa/3.0)], accessed via Wikimedia
Commons
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the CNS take on varied configurations. Throughout the body, neurons are
networked together to form neural circuits that can store and process
information [10].
1.2.2.2

The Action Potential

A neuron is able to convey information along its length in the form of an
electrical signal known as the action potential. The action potential itself is
generated by the neuron selectively allowing aqueous sodium, calcium and
potassium ions (Na+, Ca2+, and K+) from the surrounding environment to
diffuse into or out of the cell, creating an electric current that propagates
along the cell. Once the action potential reaches a synapse with another cell
it can be transmitted between neurons through a number of different
mechanisms.
Prior to the beginning of an action potential, a neuron maintains a ‘resting
potential’ of -65 mV. It is able to maintain this potential due to the action of
ion pumps embedded within the cell membrane that selectively pump sodium
and calcium ions out of the cell while pumping potassium ions into the cell.
This creates concentration gradients that are exploited to generate the action
potential. As other neurons send signals to a neuron, they transfer positively
charged ions to the dendrites of the post-synaptic neuron. This transfer of
charge is accomplished either by directly allowing ions to flow between cells
through protein channels which bridge the synaptic cleft, or via the release of
chemical signalling molecules known as neurotransmitters which open ion
channels on the post-synaptic cell.
Once the local cell membrane reaches a potential of -40 mV, voltage gated
sodium channels on the post-synaptic membrane open, allowing a large influx
of positively charged Na+ ions to diffuse into the cell. These channels remain
open for ~1 ms before closing and locking shut. As the membrane continues to
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depolarize, voltage gated potassium channels open allowing K+ to rapidly
diffuse out of the cell, repolarizing the membrane until it is slightly more
negative than the resting potential. With both the sodium and potassium
channels closed, the aforementioned sodium-potassium pumps on the cell
membrane can restore ion concentrations both within and outside the cell to
their original state. This process creates the action potential waveform. An
action potential takes about 2 ms to play out, followed by 1 ms refractory
period during which the voltage-gated channels are locked closed and the
neuron cannot fire. As the cell membrane goes through this firing cycle on the
dendrites, it changes the electric potential of the surrounding membrane
causing it to also undergo this process. In this way, the action potential
travels from the dendrites, through the cell body, to the connection between
the neuronal cell body and the axon, known as the axonal hillock. This region
of the neuron acts as a signal integrator, collecting all signals received by the
dendrites and cell body. If the sum total of all signals received by the neuron
are enough to depolarize the axonal hillock, it will generate an action
potential which will propagate down the axon and be transmitted to
downstream neurons [10], [16].
It is worth noting that the process for generating an action potential
described above simply covers neurotransmission between two neurons.
Many specialized types of neurons, particularly in sensory organs such as the
eyes or skin, can generate an action potential through a variety of
mechanisms beyond what is described above. That said, all neurons
communicate using action potentials, regardless of the means used to
generate them [10].
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1.2.2.3 Excitation and Inhibition
Neural circuits contain both excitatory neurons and inhibitory neurons; these
two neuronal classes are distinguished by the effects the have on the postsynaptic neurons they synapse with.
Excitatory neurons are the more common of the two; these neurons either
directly or indirectly transfer positive charge to downstream neurons,
bringing them closer to generating an action potential. This is achieved
through two methods; direct transmission of the action potential or through
the release of neurotransmitters. In direct transmission, ion channels
embedded within the pre- and post-synaptic sides of a synapse directly bridge
the two neurons, allowing charged ions to flow between the two cells. When
an action potential reaches a synapse, ion flow directly transfers the action
potential across the synapse allowing it to continue propagating in the postsynaptic neuron. Indirect excitation is performed through neurotransmitter
release. When the action potential reaches a synapse, it causes
neurotransmitter filled vesicles to bind to the cellular membrane at the
synapse and release the neurotransmitter into the synaptic cleft. In the
mammalian CNS, the main excitatory neurotransmitter is the molecule
glutamate (Glu). The released neurotransmitters then bind to gated ion
channels on the post-synaptic cell membrane, opening them and allowing
positive ions to flow into the neuron.
Inhibitory neurons function similarly to excitatory neurons, with the key
difference being the neurotransmitters they release. Inhibitory neurons
primarily use the neurotransmitter 𝛾–aminobutyric acid (GABA). When
released into the synaptic cleft, GABA primarily acts on chlorine channels
that allow negatively charged Cl-1 into the postsynaptic neuron. This
hyperpolarizes the post-synaptic neuron below the resting potential, making
it more difficult for it to generate an action potential. In the healthy brain,
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inhibition is used to prevent excitation of unneeded neurons within or
adjacent to a network, and to synchronize neuronal activity. It is also
important to note that GABA has a complex effect on neurons, and that
under certain circumstances it can also have a net excitatory effect on a
neuron [10], [17], [18].
1.2.2.4

The Role of Glial Cells

In addition to the neurons themselves, the CNS is composed of a diverse
family of cells collectively known as glial cells. These cells are responsible for
both protecting the neurons, and ensuring neurotransmission can occur
efficiently through a variety of mechanisms. Most importantly related to this
thesis, one type of glial cell known as the astrocyte works with neurons to
maintain the chemical environment needed for effective neurotransmission.
Astrocytes wrap around the synapses that connect neurons, and take up any
neurotransmitters released into the synapse. Once inside the astrocyte,
neurotransmitters can be broken down and their components transported
back to the neuron, where the neurotransmitter can be resynthesized as
needed. The most important example of this is the glutamate-glutamineGABA cycle, where glutamate that has been used for neurotransmission is
taken up by astrocytes and converted into glutamine. Glutamine can then
either transferred back to excitatory neurons to resynthesize glutamate, or
the astrocyte can convert glutamine into GABA for distribution to inhibitory
neurons [10], [19].
1.2.2.5

Neurotransmission and Epilepsy

In epilepsy, the process of neurotransmission and action potential generation
is altered. Epilepsy ultimately results from an imbalance of excitation and
inhibition within a neuronal network. This imbalance can be caused by
dysfunction at any point in the process of neurotransmission, including
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under-expression, over-expression, or malformations of various ion channels
that result in abnormal ion flow. These alterations create inhibitory neurons
that require extra stimulation to fire and excitatory neurons that easily fire
with minimal stimulation. Dysfunction of the astrocytes can also prevent
glutamate from being cleared from the synaptic cleft, allowing glutamate to
persistently allow positive charge into a neuron after the initial action
potential has been generated. Dysfunction of both neurons and astrocytes can
cause deregulation of the surrounding chemical environment, which can
prevent normal ion flow from repolarizing a neuron after excitation, and can
cause GABA to switch from having a net inhibitory to a net excitatory effect
[17]–[22].
While the mechanisms can vary greatly, the net effect is much the same; the
imbalance of excitation and inhibition creates a positive feedback loop in the
effected areas of cortex. Some neurons will begin to fire in a continuous or
hyper-synchronous manner, which rapidly propagates throughout the
surrounding network. Without appropriate inhibition, positive feedback loops
within the normal neural circuitry allow this abnormal firing to both
reinforce itself and propagate throughout the brain, preventing normal brain
function [11], [12], [23]. Under healthy conditions, neurons that fire together
develop stronger connections to one another through a variety of mechanisms
regulating protein expression within their synaptic connections. Seizures
stimulate these same processes, creating long-term changes that predispose
the affected neuronal circuitry to generate additional seizures in the future.
If neurons continue to fire over a prolonged seizure, excess intracellular
concentrations of ions such as Ca2+ create a neurotoxic environment,
resulting in neuron damage and death as well as proliferation of glial cells
such as astrocytes. This damage to cerebral tissue results in long-term
cognitive deficits and visible lesions in epileptic patients [5].
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1.2.3

Epileptogenesis and Epilepsy Risk Factors

Epileptogenesis, or the process by which seizure forming tissue regions
develop and grow, is a complex topic that is still not fully understood. As
stated in the ILAE definition of epilepsy, the term ‘epilepsy’ covers a wide
range of diseases and disorders that cause seizures [1]. Generally speaking
any insult to or malformation of the brain can lead to epileptogenesis, with
the main causes being traumatic brain injury, cerebral tumours, viral or
parasitic infections, malformations of the brain during development, and
genetic mutations that alter the various cellular systems used to generate
and regulate action potentials. The precise causes and mechanisms fuelling
epilpetogenesis are highly variable between patients; understanding how and
why these processes develop is an active area of research [23].
Also important to note is that epileptogenesis is an ongoing process. While
the early stages of epileptogenesis are difficult to study in humans, because
the process begins prior to a patient’s first seizure, it is known that the
location and extent of seizure forming tissue can grow and evolve over time
as seizures damage tissue and the brain responds to that damage. This
ongoing change is important to consider from a clinical perspective, as
patients with epilepsy can become more or less difficult to treat over time [1].
At present, epileptogenic processes cannot be reversed by existing epilepsy
treatments. Evidence shows certain treatments can alter the development of
epilepsy to reduce its severity in select circumstances, but there is no general
anti-epileptogenic treatment that would be a true cure for epilepsy [23].
1.2.4

Treatment

When assessing epileptic patients, neurologists assess several risk factors
that provide clues about the underlying pathology causing epileptogenesis,
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which can be used to guide treatment. These questions include any history of
head injury, whether the patient suffered from a provoked seizure (such as a
febrile seizure in infancy), and any family history of epilepsy that would
suggest a genetic component to the patient’s condition.
The primary method for treating epilepsy is the use of anti-epileptic or antiseizure drugs (AEDs). These pharmacological treatments make use of a
variety of treatment pathways; most stimulate the brain’s inhibitory
pathways to counter the increase in neural excitability that causes seizures.
AEDs are effective at controlling seizures for approximately 70% of patients
diagnosed with epilepsy, with varied effectiveness based on the type of
epilepsy syndrome [9], [24]. If a patient has tried two or more AED’s which
have failed to adequately control their seizures, or if those drugs did control
their seizures but with unacceptable side effects, then clinicians will diagnose
that patient with a drug-resistant form of epilepsy [25].
For patients with drug-resistant epilepsy, there are few treatment options
available to them. Some forms of juvenile epilepsy can be controlled by the
use of a ketogenic diet, however the efficacy of this diet in controlling adult
epilepsy is still an area of active research. The predominant treatment for
drug resistant patients is neurosurgery. A neurostimulation device is
sometimes used, but the more common treatment is resective surgery to
disconnect or remove seizure-forming regions from the rest of the brain [25].
1.2.4.1

Electroencephalography in Epilepsy

Electroencephalography (EEG) is a technique that uses electrodes to record
electrical activity in the brain. In a typical scalp EEG measurement, a
network of electrodes is placed at standardized positions around the head,
using a conductive gel to improve electrical conductivity between the skin
and the electrodes. As discussed above, neurons communicate using electrical
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currents; as neurons fire they create a change in voltage that is detected by
an EEG system. By comparing the difference in voltage between different
electrodes, brain activity can be localized to specific regions. Due to the low
voltage of the current generated by neurons, combined with the interference
created by the various layers of tissue and bone between the brain and the
scalp electrodes, EEG requires hundreds of millions of neurons to fire
simultaneously to generate detectable signal. Furthermore, the limited
current makes it challenging for scalp EEG to detect electrical activity in
deeper brain structures. EEG is very good at identifying changes in electrical
activity over time, but only gives general information as to where that
activity is occurring [10], [26].
EEG, when paired with video monitoring, is the gold standard for diagnosing
a patient with epilepsy. During an epileptic seizure, neurons begin firing with
an unnatural level of synchronicity; this results in rapid, high amplitude
changes in the EEG signal from regions affected by the seizure. Meanwhile,
most epileptic patient EEGs show what are known as interictal discharges;
abnormalities in EEG signal that suggest that a group of neurons have begun
to fire with the synchronicity found in a seizure, but without the development
of a seizure or any effects on patient behaviour [1], [26].
As discussed in more detail below, EEG is a key tool in the planning of
epilepsy surgery. In addition to traditional scalp EEG, epileptologists will
often use invasive EEG techniques, requiring either subdural or depth
electrodes. These invasive techniques work on the same principles as scalp
EEG, however the electrodes are surgically inserted into the cranial cavity to
increase sensitivity and remove the interference created by the skull and
other intervening tissues. Subdural electrodes consist of a strip of electrodes
inserted between the skull and brain across areas of interest, whereas depth
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electrodes consist of a series of electrodes embedded in a needle-like rod,
which is then inserted into the brain structures under examination [26].
1.2.4.2 Pre-Surgical Planning in Epilepsy
The success of resective surgery is highly dependant on accurate localization
of epileptic foci to ensure that all seizure forming tissue is removed while
simultaneously avoiding damage to functionally normal tissue. This
localization process is a multi-modal process utilizing a combination of
seizure semiology, EEG recordings, neuropsychological examination, and
magnetic resonance imaging (MRI). When additional diagnostic information
is needed, fluorodeoxyglucose positron emission tomography (FDG-PET), and
single-photon emission computed tomography (SPECT) are added to the
armamentarium of tools used to localize epileptogenic focus. Good surgical
outcomes are more likely for patients for whom all these techniques converge
on single clear site of dysfunction. In patients with ambiguous localization, or
seizures that emerge independently from different regions, surgery can still
have positive effects. Unfortunately, in these cases it is less likely to
completely stop their seizures because epileptic tissue that is part of the focus
can be missed in the first resection, allowing it to continue generating
seizures [25]–[28].
Typical surgical planning relies most heavily on EEG (often paired with video
recordings to capture seizure semiology simultaneously with electrographic
recordings) and MRI. EEG confirms the diagnosis of epilepsy and provides
general localization of abnormal neuronal activity, while MRI provides
imaging data to identify the extent of the abnormal tissue and help identify
the underlying disease [27]. However, 20-30% of the epileptic population,
depending on the type of epilepsy, have normal appearing clinical MRI scans
that do not display any identifiable indicators of tissue abnormality. In these
cases, FDG-PET and SPECT may be used to help localize dysfunctional
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tissue, however these techniques have their limitations. FDG-PET has high
spatial resolution, but gives no information on the underlying cause of the
seizures. In addition, the hypometabolic anomalies associated with epilepsy
on FDG-PET imaging expend well beyond the seizure focus, limiting
localization utility. Meanwhile, while SPECT scans can identify epileptic foci
using cerebral blood flow measures, SPECT results have poorer resolution
and reliability than FDG-PET [28].
In an attempt to fill this gap in epilepsy treatment, we are evaluating the use
of magnetic resonance spectroscopy in presurgical planning; it is known that
the biochemical properties of the brain are altered in epileptic regions, and it
is hoped that a spectroscopic biomarker could be used to identify the extent of
epileptic tissue in MR-normal patients.
1.3

Magnetic Resonance

Nuclear magnetic resonance (NMR) is a phenomenon that arises from the
magnetic properties of certain atomic nuclei. NMR phenomena can be
described using either classical electromagnetism or quantum mechanics;
while quantum mechanics gives a more complete explanation of NMR effects,
for almost all cases the quantum scenario simplifies to the same results as
the classical explanation. The following explanation of NMR effects will detail
the classical approach to NMR, using the formulations detailed in [29]–[31].
In the mathematical notation, vector quantities will be denoted in bolded
text.
1.3.1

Classical Electromagnetism

In general, a movement of electrical charge will generate a magnetic field.
For any object that generates a magnetic field, we can describe the magnetic
field produced by using that object’s magnetic moment 𝝁:
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𝝁=

𝑞
𝑳 = 𝛾𝑳
2𝑚

(1.1)

where q is the electric charge of the object, m is that object’s mass, 𝑳 is the
angular momentum of the object, and 𝛾 is a quantity known as the
gyromagnetic ratio. If we were to place this magnetic object within a uniform
magnetic field 𝑩𝟎 , it would experience a torque 𝜏 according to Equation 1.2:
𝜏 = |𝝁||𝑩𝟎 |𝑠𝑖𝑛𝜃

(1.2)

where 𝜃 is the angle between 𝝁 and 𝑩𝟎 . This torque would cause the cause
the magnetic moment to precess around 𝑩𝟎 with an angular frequency 𝜔
determined by Equation 1.3:
𝜔 = 𝛾𝐵0

(1.3)

For an idealized magnetic moment in a vacuum, this precession would
continue indefinitely. In a more realistic scenario, dissipative forces will act
on the magnetic object, causing it to lose the kinetic energy associated with
precession until the object reaches an equilibrium position where potential
energy is minimized:
𝐸𝑀 (𝜃) = −𝝁 ∙ 𝑩𝟎 = −|𝝁||𝑩𝟎 | 𝑐𝑜𝑠𝜃

(1.4)

The torque produced by the externally applied magnetic field vanishes when
the magnetic moment aligns parallel or anti-parallel to 𝑩𝟎 (𝜃 = 0° or 180°). If
we now introduce a network of identical magnetic moments all within the
same external 𝑩𝟎 , the magnetic moments will align with 𝑩𝟎 . By summing the
magnetic field produced by these magnetic moments, we can describe a net
magnetic field that is generated by the network.
In principle, this effect is what is occurs in an NMR experiment; the nuclei of
interest that are present within the sample generate their own magnetic
moments, which are then aligned to an external magnetic field. The scale at
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which NMR occurs complicates this picture. At the level of atomic nuclei,
thermal energy becomes a major complicating factor that prevents the neat
alignment of each nuclear magnetic moment along the applied magnetic field.
Instead, the applied magnetic field gives the otherwise randomly distributed
magnetic moments a slight bias to point along 𝑩𝟎 (which, by convention, is
oriented along the z-axis). To explore this further we will examine the NMR
behaviour of a hydrogen nucleus.
1.3.2

NMR – A Proton’s Perspective

As noted above, magnetic moments arise from a movement of charge. A
hydrogen nucleus (1H) is composed of a single proton, and that proton has a
quantum spin angular momentum. While the details of quantum spin are
beyond the scope of the current explanation, it is worth nothing that the
quantum nature of spin simplifies the current problem. Unlike a classical
rotating object, where angular momentum can be gained or lost through
interactions with the surrounding environment, quantum spin is an intrinsic
property of the particles under discussion and thus is a constant quantity.
Thus, all protons have the same constant angular momentum and by
extension the same constant magnetic moment:

𝜇 = 𝛾𝐿 =

𝛾ℏ
2

(1.5)

where ℏ is Planck’s constant. The macroscopic behaviour observed in NMR
experiments is a result of the behaviour of a large number of nuclei. To
translate these effects from an individual nucleus to a large collection of
nuclei requires the use of Boltzmann statistics. According to Boltzmann
statistics, the probability that a proton will be oriented at an angle 𝜃 with an
externally applied magnetic field 𝑃(𝜃) is:
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𝐸𝑀 (𝜃)
)
𝑘𝑇
𝑃(𝜃) =
𝜋
𝐸 (𝜃)
∫0 exp (− 𝑀𝑘𝑇 ) 𝑠𝑖𝑛𝜃 𝑑𝜃
exp (−

(1.6)

where 𝐸𝑀 (𝜃) is the potential energy of a proton at angle 𝜃 with the z-axis (see
Equation 1.4), T is the temperature of the system in Kelvin, and k is
Boltzmann’s constant. From this, the average net magnetization along the zaxis from a single proton 〈𝜇𝑧 〉 is:
𝜋

〈𝜇𝑧 〉 = ∫ 𝑃(𝜃) ∗ 𝜇 𝑐𝑜𝑠𝜃 𝑠𝑖𝑛𝜃 𝑑𝜃 ≈
0

𝛾 2 ℏ2 𝐵0
4𝑘𝑇

(1.7)

If we have a sample composed of N 1H nuclei, we can calculate the net
magnetization for a sample (𝑀0 ) by summing the contribution from each
proton:
𝛾 2 ℏ2 𝑁𝐵0
𝑀0 = 𝑁〈𝜇𝑧 〉 ≈
4𝑘𝑇

(1.8)

where N is the total number of nuclei in our system. From this, we can easily
identify the experimental factors that affect the strength of the NMR effect;
the number of 1H nuclei in the sample, sample temperature (measured in
Kelvin), the strength of our applied magnetic field, and the gyromagnetic
ratio of the nucleus being examined.
It is worth noting at this point that the behaviour derived above can be
extended to other atomic nuclei beyond 1H. The mathematics involved are the
same in principle, but are complicated by the presence of additional nucleons;
as with the proton, the neutron also has quantum mechanical spin and
generates its own dipole moment; these moments add to produce the
magnetic moment of a more complex nucleus. Here the gyromagnetic ratio
becomes an important factor; larger and more complex nuclei have a smaller
charge to mass ratio. This results in a smaller gyromagnetic ratio, which in
turn means a smaller 𝑀0 is generated for larger nuclei under constant
experimental conditions. This fact, combined with the naturally high
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abundance of 1H in biological systems has made hydrogen the primary
nucleus of interest in medical applications of NMR.
1.3.3

Excitation

The utility of NMR comes from our ability to link the physical properties of
the sample to the behaviour of sample magnetization. There is very little
useful information that can be gleaned from simply measuring sample
magnetization while is it statically aligned along the z-axis (often referred to
in NMR as the longitudinal axis). However, if we can push sample
magnetization away from equilibrium such that it has a component in the xyplane (also know as the transverse plane), the natural precession of
magnetization around 𝐵0 can be manipulated to reveal a wide range of useful
information. Transverse magnetization is typically generated by applying a
second, time varying magnetic field 𝐵1 (𝑡) which oscillates sinusiodally with
the same frequency as the precessing nuclei in our sample (𝜔), known as the
Larmor frequency:
𝐵1 (𝑡) = |B1 (𝑡)|sin 𝜔𝑡

(1.9)

This has the effect of rotating the entire distribution of magnetic moments
away from the z-axis by an angle determined by the duration and amplitude
of the pulse used.
In modern NMR techniques, pulsed 𝐵1 (𝑡) fields, where the amplitude of 𝐵1 (𝑡)
is modulated over time, are almost universally used. The oscillatory
frequency for this pulse as defined in Equation 1.9 falls into the radio
frequency range for NMR experiments; as a result, 𝐵1 (𝑡) is commonly
referred to as a radiofrequency (RF) pulse. A given RF pulse will excite signal
across a range of frequencies centered on the Larmor frequency. To take
advantage of this, the amplitude modulation of 𝐵1 (𝑡) in the time domain is
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specifically tailored to give a desired frequency selection profile, while the
duration of the pulse can be changed to give a desired frequency bandwidth.
1.3.4

Signal Detection

Detection of NMR signal relies on the principles of electromagnetic induction,
which describes how a changing magnetic field generates electrical currents
within a conductor:

Φ𝐵 = ∫ 𝑩(𝒓, 𝑡) ∙ 𝑑𝑨
𝜖= −

(1.10)
(1.11)

𝑑Φ𝐵
𝑑𝑡

where 𝜖 is the voltage generated, A is the area of the conductor where voltage
is being induced, and Φ𝐵 is the magnetic flux through this area. In a simple
NMR experiment, signal detection is achieved by placing a simple loop of
wire adjacent to our sample with its cross sectional area parallel to 𝑩𝟎 . In
this position, the precessing magnetization generates a sinusoidally varying
voltage within the loop, which can then be measured as NMR signal. More
complex NMR and MRI systems make use of more complicated conducting
arrays that exploit this same principle, but are able to collect more detailed
information over a region of interest.
1.3.5

Relaxation

Once magnetization has been pushed into the transverse plane, a variety of
mechanisms will return it to equilibrium in a process known as relaxation.
This process occurs exponentially, as described by Equations 1.12 and 1.13:

𝑀𝑧 (𝑡) = 𝑀0 (1 − 𝑒
𝑀𝑋𝑌 (𝑡) = 𝑀0 𝑒

−

−

𝑡
𝑇1 )

𝑡
𝑇2

(1.12)
(1.13)
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where 𝑇1 is the relaxation constant which dictates how fast equilibrium
magnetization is restored along the longitudinal axis, 𝑇2 is the relaxation
constant which dictates haw fast signal in the transverse plane disappears,
and t is the time elapsed since excitation.
Relaxation is heavily dictated by the microenvironment experienced by
individual magnetic moments within a sample. Molecular motion and the
precession of neighbouring magnetic moments cause small fluctuations in the
magnetic field seen by a given magnetic moment. In 𝑇1 relaxation, these local
fluctuations cause precessing nuclei to lose energy to the surrounding
environment. This energy loss only occurs when the fluctuations occur at or
near the Larmor frequency. It is worth highlighting that 𝑇1 relaxation is
effected by 𝑩𝟎 field strength. Equation 1.3 shows that the Larmor frequency
depends on 𝑩𝟎 ; as 𝑩𝟎 increases, higher frequency fluctuations are required to
return magnetization to the z-axis. As the frequency of molecular motion
within our sample is constant with magnetic field, this increase in 𝑩𝟎
lengthens 𝑇1 relaxation by increasing the frequency separation between
molecular motion and resonance frequency.
𝑇2 relaxation is caused by similar mechanisms, but crucially in 𝑇2 relaxation
energy is simply exchanged between moments within a sample and there is
no net energy loss to the surrounding environment. When signal is excited in
an NMR experiment, transverse relaxation is created by the coherent
precession of nuclei around 𝑩𝟎 . Fluctuations in the field seen by each nucleus
causes variations in precession frequency, leading to a loss of coherence and
hence a loss in transverse magnetization over time. This loss of coherence
largely results from low frequency magnetic fluctuations; these effects are
amplified as we move to very high field strengths, leading to shorter 𝑇2
relaxation times.
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Up to now we have assumed that the applied 𝐵0 is an ideal, completely
uniform field. In reality this field is generated over a finite region and hence
is heterogeneous to some degree across a sample. In addition, the sample has
an effect on 𝐵0; different materials have different magnetic properties, and
when there is a transition between different materials within a magnetic
field (such as the transition between a sample and the surrounding air)
fluctuations in 𝐵0 occur. Modern MRI systems come equipped with hardware
known as shimming coils that are used correct for gross inhomogeneities in
𝐵0; however, small variations are omnipresent in any real NMR experiment.
These non-idealities are important from a relaxation standpoint as they can
dramatically speed up transverse relaxation. For a given magnetic moment,
the resonance frequency depends on the total local magnetic field
encountered by that moment; generalizing Equation 1.3, we find:
𝜔 = 𝛾𝐵 = 𝛾(𝐵0 + ∆𝐵)

(1.14)

where ∆𝐵 represents any variation in 𝐵0 due to magnetic inhomogeneities,
applied 𝐵1 fields, or applied magnetic gradients (discussed below).
These shifts in the resonance frequency across the sample due to 𝐵0
inhomogeneities causes our magnetization to dephase much more rapidly
than theoretical 𝑇2 decay. However, because these inhomogeneities are
constant in time and space their effect can be reversed using by RF pulses to
invert phase. For this reason, the simple observed transverse relaxation in a
given experiment is referred to as 𝑇2∗ decay, and we reserve the term 𝑇2
relaxation for the irreversible decay previously described (Figure 1.5).
1.3.6

Gradients

The most powerful tool available to link the physical properties of a sample to
its magnetization is the magnetic gradient. By applying a linearly varying
magnetic gradient across a sample, we can linearly vary the resonance
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Figure 1.5 - Simple Pulse
Sequences Illustrating
Relaxation Effects: (A) shows
a Free Induction Decay where
signal decays exponentially at
the rate T2* (dotted line). (B)
shows a Spin Echo where the
echo rises and falls
exponentially according to T2*.
(C) shows a Carr-PurcellMeiboom-Gill (CPMG) echo
train, which uses a series of 180
degree RF pulses to refocus an
echo multiple times. Here the
maximum amplitude of each
echo decreases exponentially at
the rate T2.
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frequency of nuclei across our sample in a highly controlled manner (see
Equation 1.14). This creates a spatial dependence between signal phase and
position that has two main uses.
When applied in conjunction with an RF pulse, an applied magnetic gradient
can excite signal from a slab or slice of the sample, and is known as a slice
select gradient. As mentioned above, RF pulses excite signal from any
precessing moments that fall within a certain frequency range around the
Larmor frequency. By varying the strength of a magnetic gradient, signal
from specific slices of the sample can be excited and acquired, allowing for
localized NMR measurements within a large or heterogeneous sample.
Gradients are also fundamental for producing images. The relationship
created between resonance frequency and position created by magnetic
gradients can be exploited to produce dependence between the position of a
magnetic moment within the MR system and its phase. Stated simply, the
inverse Fourier transform of an NMR signal acquired in the presence of a
magnetic field gradient returns the frequency distribution of the signal
induced by the gradient, which can be used to recover the spatial distribution
of magnetization, producing an image of the sample.
1.3.7

Magnetic Resonance Spectroscopy

Magnetic resonance spectroscopy (MRS) is a technique that allows for the
identification and quantification of different chemical species within a
sample.
1.3.7.1

Chemical Shift

Prior to this discussion, we have been tacitly assuming that our hypothetical
sample was composed exclusively of 1H nuclei. In reality, this picture is
complicated by the presence of chemical structure within a sample and the
electrons that form these structures. As with protons and neutrons, electrons
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generate their own magnetic dipole that causes a slight local variation in 𝐵0.
This causes a shift in the resonance frequency between 1H nuclei attached to
different molecules, and between chemically non-equivalent 1H nuclei within
the same molecule. These variations from the Larmor frequency occur by a
fixed percentage (usually measured in parts-per-million, ppm) and are
heavily dependent on the chemical structure of the molecule. Magnetic
resonance spectroscopy exploits this behaviour to identify different chemical
species. Using the Fourier transform, a time-domain signal collected from an
NMR system is decomposed into its frequency components, allowing us to
visualize the resonance frequencies present within a sample. Using either
computer simulations or phantom measurements of a single molecule of
interest in isolation, the characteristic pattern of frequency shifts, peak
amplitudes, and phases can be modeled for that molecule of interest. This
information is then used to identify that molecule from a more complicated
spectrum composed of many molecules (Figure 1.6).
The signal amplitude in NMR is proportional to the number of nuclei
generating that signal. Following a Fourier transform, this relationship
results in the number of nuclei involved instead being proportional to the
area under the corresponding spectral peak. This allows the concentration of
chemicals to be measured quantitatively by comparing the area under the
spectral peaks of different molecules to a reference signal with known
concentration.
1.3.7.2

J-coupling

While chemical shift is primarily responsible for MRS phenomena, these
spectra are further shaped by the phenomenon of J-coupling. To explain Jcoupling we must briefly invoke quantum mechanics. In quantum mechanics
there is a principle known as Pauli’s exclusion principle. This rule simply
states that particles with half integer spin cannot occupy the same quantum
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state within the same system simultaneously (i.e. different particles within a
system must be distinct). Protons, neutrons, and electrons all have half
integer spin and hence all follow this rule. However, for our purposes this
principle is most important for the electron.
When bound to an atom or molecule, electrons are confined by quantum
mechanics to a discrete set of orbitals surrounding their parent nuclei; each
orbital can contain up to two electrons. Electrons within the same orbital by
definition share many quantum properties, leaving quantum spin (m) as the
only variable that can be used to distinguish between them. As a result, for
pairs of electrons within the same orbital, one electron must be in a spin
down state (𝑚 = ½), and the other must be in a spin up state (𝑚 = − ½).
When applied to the electrons that bind a molecule together, the exclusion
principle provides a mechanism for nuclei to affect the chemical shift of other
nuclei they are chemically bonded to. The polarization of one nucleus along
the z-axis in a molecule will affect the polarization of its accompanying
electrons. This restricts the polarization of electrons from other nuclei that
share orbitals connecting the first nucleus to a second, thus subtly affecting
the chemical shift of this second nucleus. This effect is not simply restricted
to adjacent nuclei, but can alter the signal from chemically distinct nuclei up
to 3 chemical bonds away from one another.
In an MR spectrum, this effect causes spectral peaks to be split into multiple
daughter peaks (Figure 1.7). This information can be useful because it
contains information about the structure of the molecule. However,
depending on the strength of the coupling, this can lead to a substantial
decrease in the signal to noise ratio (SNR) of a spectrum, and cause
significant overlap between signals from different molecules, increasing
measurement difficulty.
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Figure 1.6 – Fit 7T semi-LASER Spectrum Collected from the Hippocampus:
Spectrum collected from a human hippocampus (blue), overlaid with fit spectrum (orange)
and residual noise (green). Below, the fit spectrum is broken down into the contributions
from individual metabolites. Data was acquired using a semi-LASER sequence (See section
1.3.7.6)

30

Figure 1.7 - Example J-coupling Multiplets: Example multiplets from NMR experiments; if J-coupling were not a factor, all these
multiplets would stack on top of one another to create a single, high amplitude peak.
Multiplet image by ChemistHans at English Wikipedia [Public domain], via Wikimedia Commons
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1.3.7.3

Spectroscopic Techniques

To collect a spectrum one simply has to excite nuclei within the sample, then
record and Fourier transform the resulting signal waveform. However,
particularly for medical applications, spatial localization of spectroscopic
signal is necessary to identify metabolic change in abnormal, diseased, or
damaged tissue. As a result, a variety of techniques have been developed to
encode spatial information. The simplest forms of localized spectroscopic
techniques are known as single voxel techniques; these techniques collect
bulk signal from a specific region of interest. In all single voxel techniques,
three slice selective gradients applied across the x-, y-, and z-axes are used to
selectively excite signal from the region of interest. For a more detailed view
of a region of interest, magnetic resonance spectroscopic imaging (MRSI) can
be used. This technique involves collecting spectra from voxels arranged in a
grid pattern across a region of interest to generate maps of different
metabolite levels across that region.
The key limitation on the use of spectroscopic techniques in medical practice
is the low concentration of most metabolites in vivo. As shown in Equation
1.8, sample magnetization (and hence sample signal) is proportional to the
number of relevant nuclei being excited. While water is highly concentrated
in tissue (with an average concentration of ~50 M in the human brain), many
of the metabolites of interest in in vivo NMR have relatively low
concentrations on the order of mM. This has two effects; first, to accurately
quantify metabolite signal, water suppression techniques must be employed
to prevent water signal from completely overwhelming the rest of a spectrum.
Second, the low metabolite signal results in a low SNR for these spectral
peaks. To accurately quantify metabolite levels, signal averaging is often
necessary to boost SNR, which results in long scan times that are not ideal in
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a clinical environment. This is particularly true for MRSI techniques that
require the collection of multiple spectra across a sample.
1.3.7.4

Data Analysis Methods and Techniques

In MRS, the exact data analysis steps taken to convert from an MRS
spectrum to a measure of concentration varies between different research
groups. Discussed here will be the analysis techniques used for the research
presented in Chapter 2.
Prior to analysis, spectral data typically undergo some pre-processing to
improve spectral quality. Time and spatially varying field inhomogeneities
may distort the shape of the peaks within a spectrum, making the
quantification process more difficult. To reduce this effect, various lineshape
corrections are possible. In this study presented in Chapter 2, we utilized a
combined QUALITY deconvolution [32] and eddy current correction [33]
(QUECC) technique to ensure spectral peaks all had a Lorentzian lineshape
[34].
Metabolite concentration is calculated from an MRS spectrum based on the
relationship between the number of nuclei generating a signal and the signal
amplitude. By measuring the amplitude associated with each metabolite in
the time domain, concentration can be calculated. This amplitude is
measured by fitting a simulated metabolite prior knowledge lineshapes,
generated using the PyGamma pulse sequence simulation tools [35], to the
acquired data. A Levenberg-Marquard minimization routine is used to
minimize the difference between the data and the prior knowledge
lineshapes. The model is constrained in how it can fit the data to ensure
errors do not occur; for example, if the fit for a specific spectral peak falls
outside of the given constraints, then that peak’s time domain amplitude is
fixed to zero and fitting is re-started. Once the data is accurately fit, the

33
signal amplitudes of each metabolite determined from the fit are used to
calculate concentrations [36], [37].
Concentration is commonly calculated in the brain either as absolute values
in mM using water as an internal reference signal, or as a ratio to the
molecule creatine (Cr). Ratios to creatine were calculated by summing the
peak amplitudes that contribute to a particular metabolite spectrum, then
dividing by the total amplitude of Cr (Equation 1.15):

𝑋⁄𝐶𝑟 =

(1.15)

Σ𝑆𝐴𝑚𝑝,𝑋
Σ𝑆𝐴𝑚𝑝,𝐶𝑟

where 𝑋⁄𝐶𝑟 is the concentration of the metabolite of interest X as a ratio to
Cr, and Σ𝑆𝐴𝑚𝑝,𝑋 and Σ𝑆𝐴𝑚𝑝,𝐶𝑟 are the total amplitude of all peaks that form the
spectral line shape of the metabolite of interest and Cr.
Absolute concentration calculations, which give metabolite concentration
within the combined grey/white matter tissue fraction of the voxel, were
evaluated using Equation 1.16:

[𝑋] 𝑇𝑖𝑠𝑠𝑢𝑒 =

Σ𝑆𝐴𝑚𝑝,𝑋 𝑛𝜌,𝐻2 𝑂 𝑅𝐻2 𝑂
∗ [𝐻2 𝑂]𝑉𝑜𝑥𝑒𝑙 ∗ (𝐺𝑀 + 𝑊𝑀)
Σ𝑆𝐴𝑚𝑝,𝐻2 𝑂 𝑛𝜌,𝑋 𝑅𝑋

𝑅𝑋 = 𝐺𝑀 (1 − 𝑒

−

𝑇𝑅
𝑇𝐸
−
𝑇1,𝐺𝑀 ) (𝑒 𝑇2,𝐺𝑀 )

+ 𝑊𝑀 (1 − 𝑒

−

𝑇𝑅

(1.16)

(1.17)
𝑇𝐸

−
𝑇1,𝑊𝑀 ) (𝑒 𝑇2,𝑊𝑀 )

Where [𝑋]𝑇𝑖𝑠𝑠𝑢𝑒 is the concentration of the metabolite of interest within the
tissue fraction of the MRS voxel, 𝑛𝜌,𝐻2 𝑂 and 𝑛𝜌,𝑋 are the number of protons
producing spectral signal for both water and the metabolite of interest, 𝑅𝑋
and 𝑅𝐻2 𝑂 are the combined 𝑇1 and 𝑇2 relaxation for both the metabolite of
interest and water in grey and white matter (See Equation 1.17), [𝐻2 𝑂]𝑉𝑜𝑥𝑒𝑙 is
the average concentration of water within the voxel, and (GM+WM) is the
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voxel tissue fraction for grey and white matter [38]. This last correction was
included to ensure that the calculated metabolite concentration was the
average concentration within the tissue component of the voxel, and not from
the voxel as a whole. For this calculation, voxel tissue volume fractions were
evaluated using the Oxford Centre for Functional MRI of the Brain (FMRIB)
software library (FSL) [39]; images were brain extracted and segmented
using FSL's Brain Extraction Tool (BET) [40] and FMRIB's Automated
Segmentation Tool (FAST) [41]. Literature reported relaxation and water
concentration values were used for this calculation [42]–[45].
1.3.7.5

Effects of Field Strength in Spectroscopy

As previously mentioned, the low concentration of metabolites in vivo results
in a low SNR in MRS measurements, which in turn decrease the clinical
utility of MRS by requiring long scan times. Looking back to Equation 1.8,
the only factor that can be manipulated to increase SNR for an in vivo
measurement is 𝐵0 . In addition, as mentioned in the discussion of chemical
shift, the shift between different spectral peaks is a fractional change away
from the Larmor frequency. By increasing 𝐵0, the frequency separation
between different spectral peaks increases (spectral dispersion), making it
easier to separate overlapping peaks, allowing for the independent
measurement of metabolites that are heavily overlapped at lower field
strengths. For these two reasons, MRS can greatly benefit from an increase
in 𝐵0 field strength, leading to a push to perform MRS on the strongest
possible magnets.
However, while an increase in 𝐵0 had considerable benefits, it also increases
magnetic field inhomogeneities in biological tissues. MRS relies on the
resolution of frequency shifts to identify different molecules. However,
frequency shifts can also be caused by variations in 𝐵0 within a region of
study. With 𝐵0 variation, spectral peaks become wider and the SNR of a
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collected spectrum decreases, potentially countering the benefits of higher
field strength. Importantly, magnetic susceptibility artefacts increase with
𝐵0. At ultra-high field strengths (≥ 7T), these non-uniformities must be
corrected using a combination shimming hardware and inhomogeneity
insensitive MRS pulse sequences to preserve the benefits of increased field
strength. In addition, the increase in Larmor frequency requires higher
energy B1 fields, which are in turn harder to generate uniformly across a
sample, and can lead to power deposition restrictions.
An additional source of error in MRS localization that increases with field
strength is the chemical shift displacement error (CSDE). Spatial localization
is achieved for MRS primarily through frequency selective excitation; a
gradient is applied across a sample, then an RF pulse excites signal from a
specific range of frequencies that correspond to the region of interest.
However, in MRS the excited signal contains substantial contributions from
metabolite peaks that are not oscillating at the Larmor frequency prior to
gradient application. This means that the signal from each spectral peak
comes from a slightly different voxel, with a displacement given by Equation
1.18:

Δ𝑥 =

Δ𝜔
𝑉
Δ𝜔𝑚𝑎𝑥 𝑥

(1.18)

where Δ𝑥 is the change in position for the centre of the voxel along the x-axis,
Δ𝜔 is the chemical shift between two spectral peaks, Δ𝜔𝑚𝑎𝑥 is the bandwidth
of the slice selective RF pulse, and 𝑉𝑥 is the voxel length along the x-axis. To
minimize CSDE either high powered gradients, or high bandwidth RF pulses
must be used during slice selection [30].
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1.3.7.6

Semi-LASER

Localization by adiabatic selective refocusing (LASER) [46] is a spectroscopy
localization sequence designed to acquire high quality MRS spectra from well
defined voxels at ultra-high field strengths. A slight variant of this sequence
called semi-LASER uses a simple, slice selective sinc shaped 90° RF pulse to
excite signal, followed by two pairs of slice selective adiabatic full passage
(AFP) pulses to localize signal to a single voxel of user specified dimensions
(Figure 1.8). The sequence produces a spin echo; the second half of the echo is
acquired and Fourier transformed to produce the MRS spectrum.
Adiabatic pulses are a class of RF pulse that are both modulated in
amplitude and frequency over the duration of the pulse. Theses pulses are
designed to be less sensitive to 𝐵1 inhomogeneities than conventional pulses,
and therefore particularly useful for high field applications where 𝐵1 may
vary across a sample. In addition, adiabatic pulses can be designed to have
large excitation bandwidths with arbitrarily long pulse durations. This has
several advantages; for example, increasing pulse length allows for a
decrease in pulse amplitude, which in turn reduces power deposition.
Furthermore, high bandwidth pulses reduce chemical shift artefacts [30],
[47], [48].
There are also drawbacks associated with adiabatic pulses; for example, they
take a long time to play out, resulting in long echo times that reduce SNR.
Also, when used for slice selection, proper refocusing can only be achieved by
using paired adiabatic pulses. This increases the total number of pulses and
increases overall power deposition. The semi-LASER sequence is designed as
a happy middle ground between more conventional single voxel techniques
and LASER. In semi-LASER, localization is achieved using two slice selective
AFP pulse pairs and a slice selective normal RF pulse at the beginning of the
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Figure 1.8 - The semi-LASER Pulse Sequence: In this sequence, initial excitation is
performed with a 90° sinc shaped slice select pulse. This is followed by two pairs of slice
select adiabatic full passage pulses, which localize signal to a voxel within the sample while
refocusing signal into a spin echo. The decay of this echo is then acquired and Fourier
transformed to give an MRS spectrum
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sequence, creating a balance between reduced echo time and power
transmission [30], [47], [48].
1.4

Spectroscopy in Temporal Lobe Epilepsy

MRS was first applied to the study of human epilepsy in the late 1980’s, with
TLE being one of the first epilepsies examined [49]. In the decades since,
dozens of research groups have examined TLE with MRS, the results of
which are summarized below based on the metabolite of interest.
1.4.1

Creatine

Biologically, Cr acts as a buffer for cellular energy metabolism. Cr exists in
two main forms in the human body; molecular creatine, and phosphocreatine
(PCr). The enzyme creatine kinase can rapidly convert between these two
molecules via the following reaction:
𝐶𝑟 + 𝐴𝑇𝑃 ↔ 𝑃𝐶𝑟 + 𝐴𝐷𝑃 + 𝐻 +
turning adenosine triphosphate (ATP) into adenosine diphosphate (ADP) or
vice versa in the process. ATP is the primary energy-carrying molecule in
cellular processes; by storing high-energy phosphorus bonds in PCr, the cell
creates an energy reservoir that can be used to rapidly replenish ATP levels
in response to increased energy consumption. Furthermore, PCr is able to
diffuse much faster throughout a cell than ATP, allowing for more efficient
energy transport. In in vivo MRS studies, the signal from both forms of Cr
overlap significantly with one another in the spectrum. As a result, Cr
concentration is commonly measured as the total concentration of these two
molecules [30], [50].
Creatine is particularly noteworthy in MRS studies of the brain in general
because its concentration in vivo has been shown to be invariant with age
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and invariant between healthy and diseased tissue in some diseases. This
suggests that Cr is a good candidate as a reference signal with which to
quantify other metabolites. As a result, many MRS studies report metabolite
concentration as a ratio of the metabolite of interest to Cr (denoted as X/Cr).
However, more recent work has shown that Cr is not constant between
healthy and diseased tissue under a variety of conditions, making its use as a
reference signal a potential source of error [30], [50]. Some argue that the
potential variance in concentration undermines the accuracy of MRS
measurements [50], whereas others have commented that normalization to
creatine still gives a useful measurement, as it potentially normalizes for the
amount of biomass within a measured region [51].
In epilepsy, due to its common use as a reference signal, few studies report on
the behaviour of Cr directly. In one study [9], Cr levels (measured as an
absolute quantity using an internal water reference, hereafter denoted by
enclosing metabolite shorthand within [square brackets]) were found to
increase ipsilateral to seizure focus in patients with drug-resistant mesial
temporal sclerosis. Meanwhile other studies did not observe changes in [Cr]
in TLE patients with hippocampal sclerosis or in MRI-negative TLE patients
[52], [53]. In another study [54], high resolution scans of resected epileptic
tissue found that elevated [Cr] levels were associated with elevated seizure
frequency, but were not different between samples with hippocampal
sclerosis compared to samples with no visible lesion.
1.4.2

N-Acetylaspartate

N-Acetylaspartate (NAA) is one of the most highly concentrated metabolites
within the brain; this in combination with its very prominent methyl singlet
peak at 2.01 ppm makes it the easiest metabolite to measure in an in vivo
spectrum. It is exclusively synthesized in neuronal mitochondria, making it a
biomarker for neuronal health and density. NAA levels have been found to
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decrease across a wide range of neurological disorders, and have been found
to recover in some diseases in response to treatment [30], [50].
In TLE, decreased NAA levels ipsilateral to seizure focus are the most
commonly reported metabolic changes, both when measured as the ratio
NAA/Cr [55], [56] or NAA/(Cr+ Cho) [57]–[60], and as an absolute quantity
[9], [52]. Studies have also found that NAA change is not limited to the
epileptic focus; decreases in NAA have been reported outside of visible lesions
ipsilateral to seizure focus [56], contralateral to seizure focus [55], and
various regions of the frontal lobe [61], [62]. Using an MRSI technique, one
study [63] showed that when the area of greatest NAA/Cr abnormality was
resected, patients had better clinical outcomes. In MRI-normal TLE patients,
changes in NAA appear to be less distinct. Some report the same NAA
decrease as that seen in lesional TLE [64], while others report no difference
between MRI-normal patients and healthy controls [52]. NAA levels may also
be affected by seizure activity, as one study has found decreases in NAA/Cr,
NAA/Cho, and NAA/(Cr+ Cho) when comparing patients immediately post
seizure to their inter-ictal baseline [65].
1.4.3

Choline

The choline (Cho) signal in NMR is the product of signal from a variety of
choline containing molecules, namely free choline, phosphocholine, and
glycerophosphocholine. These 3 molecules are all involved in the process of
phospholipid synthesis and degeneration, and as a result changes in Cho in
MRS are largely associated with membrane turnover. It is also important to
note that Cho is readily transported across the blood brain barrier, as the
brain does not synthesize enough to meet its needs. As a result, Cho levels in
the brain can be affected by diet. Cho is the second most prominent peak from
human brain spectra, because it contains 9 chemically equivalent protons
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that do not experience substantial chemical shift effects between different
Cho containing metabolites [30], [50].
In TLE, Cho is commonly included into the combined measure NAA/(Cho+Cr)
or NAA/Cho, both of which have been shown to decrease ipsilateral to seizure
focus [56], [57], [60], [62], [65]. In cases Cho is reported, it has been found to
increase ipsilateral to seizure focus [9] or has shown no significant change
[66]. In resected tissue, [Cho] was found to be lower in lesional TLE tissue
compared to MRI-normal tissue [54].
1.4.4

Glutamate and Glutamine

Glutamate (Glu) is the highest concentration amino acid in the central
nervous system. However, unlike NAA or Cho none of the 5 protons on the
Glu molecule are chemically equivalent. As a result, the Glu spectrum is split
into a large number of low amplitude peaks. Furthermore glutamine (Gln),
the precursor molecule for Glu, is structurally very similar to glutamate; this
results in a high level of overlap between the spectra for these two molecules
making them very hard to resolve independently at clinical field strengths.
As a result, for in vivo studies they are almost always reported as a combined
concentration (Glx).
Biologically, glutamate is important because it is the primary excitatory
neurotransmitter in the CNS. Importantly for epilepsy, Glu can also be
neurotoxic. One of the receptors Glu activates allows positively charged Ca2+
ions into a neuron, which in sufficient quantities can cause cell death.
Meanwhile, glutamine is a molecule that is synthesized from Glu in
astrocytes. After a neuron releases Glu during neurotransmission, that Glu is
taken out of the synaptic cleft by astrocytes. It is then converted from Glu to
Gln so it can be safely transferred back to the neuron for re-synthesis of Glu
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in what is known as the Glu-Gln cycle. In addition, Gln is used to synthesize
the primary inhibitory neurotransmitter, GABA [30], [50].
In epilepsy, dysfunction of the Glu-Gln cycle is considered one of the potential
causes of seizures, making Glx studies a key area of interest [8]. In TLE, the
region of the brain involved further complicates evaluation of Glx.
Specifically, the proximity of the temporal lobe to the base of the skull and
sinuses results in increased 𝐵0 heterogeneity. This decreases the SNR of the
spectrum and makes it challenging to separate Glx signal from noise at
clinical field strengths. Of the studies that do report Glx levels, two did not
find significant changes[66], [55], one found Glx/Cr decreased ipsilateral to
seizure focus compared to controls and contralateral tissue [58], one found a
significant increase in [Glu] and [Gln] in lesional TLE tissue compared to MR
normal tissue [54], and one found that Glu increased in the frontal lobe of
TLE patients [52].
1.4.5

Myo-Inosotol

Myo-inositol (Myo) is the most prevalent form of inositol in the human body.
Within the CNS, Myo is understood to take on several roles; it is part of the
lipid component of biological membranes, it is an osmolyte used to maintain
cell volume, and it both acts as and is used to synthesize secondary
messenger molecules for intra-cellular communication. As with Cho, Myo is
transported across the blood brain barrier and is primarily sourced both from
synthesis elsewhere in the body and from dietary supplementation. In MRS,
Myo has been proposed as a biomarker for glial cell activity. However, Myo
has been shown to be taken up by neurons as well as glial cells, leading to
questions about its specificity [30], [50].
In the study of TLE, levels of Myo/Cr have been reported to decrease
ipsilateral to seizure focus in MRI-normal TLE patients [58], to increase
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ipsilateral to seizure focus in patients with hippocampal sclerosis [52], and to
decrease in frontal lobe in TLE patients [52], [61].
1.5

Thesis Outline

To address our research question outlined in Section 1.1, we performed an
MRS study of non-lesional TLE patients to identify metabolic abnormalities
associated with this patient group. This study and its results are detailed in
Chapter 2. The final chapter contains a brief overview of our results thus far,
and the future direction in which this work could be taken.
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Chapter 2
7T Magnetic Resonance Spectroscopy of the
Hippocampus in Non-Lesional Temporal lobe
Epilepsy

52
2.1 Introduction
Temporal Lobe Epilepsy (TLE) is one of the most common forms of focal
epilepsy. Approximately 25-30% of patients with TLE have inadequate
control over their seizures with drug treatments and are ultimately
diagnosed with medically refractory epilepsy (MRE). Such patients are
considered candidates for more invasive treatments such as surgical resection
of the affected tissue. While resective surgery has a reasonably high success
rate in this cohort, the effectiveness of surgery is diminished in patients
without an identifiable structural abnormality on clinical magnetic resonance
imaging (MRI) scans to guide the resection [1], [2].
These localization issues are not unique to TLE. One potential technique to
help identify epileptic tissue in the MRI-normal population is the use of
magnetic resonance spectroscopy (MRS). MRS techniques can discriminate
different molecular species present within a tissue of interest using the
unique spectral lineshape of each molecule determined by its chemical
structure, and measure the concentration of these molecules. Unfortunately,
the application of MRS in TLE is hampered by the proximity of many key
structures of the temporal lobe, such as the hippocampus, to structures in the
head with different magnetic susceptibility to that of the tissue. Specifically,
the base of the skull and the sinuses distort the magnetic field produced by
the MR system, greatly reducing the signal to noise and overall quality of the
resultant spectrum [3]. Most studies which examine metabolites with low
MRS signal amplitudes within the temporal lobe have been forced to use
either large voxel volumes, leading to ambiguity in the results due to the
inclusion of multiple separate brain structures within the same voxel [4], [5],
or they have restricted the metabolites under examination to those that can
be accurately quantified in spite of poor spectral quality: N-acetylaspartate
(NAA), total creatine (Cr), and total choline (Cho) [6]–[11].
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Several studies have previously examined non-lesional TLE. Decreases in
NAA, NAA/Cr, and NAA/(Cr+ Cho) [7], [12]–[15] within the temporal lobe
ipsilateral to seizure origin have been most consistently reported, although
one study also showed no significant metabolite changes [4]. In addition,
some metabolite changes have been found outside the temporal lobe in nonlesional patients using both single voxel MRS and MRS imaging techniques.
These studies have shown ipsilateral and extra-temporal decreases in
NAA/(Cr+ Cho) [12], [13], [NAA] [16], and myo-inositol [4], [16], in addition to
variable glutamate behaviour [4], [13]. Resected MRI-normal tissue has also
been studied using high resolution magic angle spinning, revealing decreases
in glutamate and glutamine and increases in NAA and Cho when comparing
non-lesional tissue samples with samples containing hippocampal sclerosis
[17].
The use of ultra high field human MRI scanners (≥7T) can improve MRS
measurements in hard to measure regions of interest such as the
hippocampus. The increased main magnetic field strength increases the
signal to noise ratio (SNR) of the acquired spectra, while simultaneously
increasing spectral dispersion, thereby reducing signal overlap and allowing
metabolite signals to be resolved separately. In addition, higher power shim
coil amplifiers can better correct field inhomogeneities, thereby improving
magnetic field homogeneity within the tissue and consequently spectral
quality [18]. The goal of the current study was to examine MRS changes in
the hippocampus in TLE patients at 7T to confirm decreases in NAA and
increases in Cho concentrations demonstrated by previous studies, while also
examining previously hard to measure metabolites such as glutamate,
glutamine, and Myo-Inositol.
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2.2 Methods
2.2.1 Patient Recruitment
Patients between the ages of 18 and 90 were recruited through the Epilepsy
Program at the London Health Sciences Centre. All participants provided
informed consent for this study, which was approved by the Western
University Health Sciences Research Ethics Board. All patients had been
diagnosed with MRI-negative TLE during routine clinical treatment. Prior to
recruitment, all patients underwent scalp and/or intracranial
electroencephalography (EEG) and a 1.5T MRI scan as part of standard
clinical care. Patients were excluded if they were unable to tolerate the 7T
MRI scan protocol, if any vascular malformations or tumours were detected
on their clinical MRI, or if they suffered from any other significant medical or
psychiatric conditions. Age, sex, and handedness matched participants were
also recruited to serve as a control group.
In total, 24 patients were recruited, along with 24 healthy controls. Of these,
useable data from at least one hippocampus were acquired from 19 patients
(14 male, 6 female, average age 31.8± 11.6 years) and 20 healthy controls (14
male, 7 female, average age 32.4± 8.6 years). MRS data was not collected
from the excluded participants either because of hardware issues or because
patients could not tolerate the scan due to claustrophobia. Demographic
information for all included patients is provided in Table 2.1, including side
of seizure localization and duration of epilepsy. Acquired spectra were
excluded from analysis if they had a signal-to-noise ratio <10 (N=3) and/or if
the linewidth was greater than 24 Hz (N=2). Full datasets including spectra
from both left and right hippocampi were obtained from 15 patients, while
only a single useable spectrum was obtained from the remaining four
patients. Full datasets were collected from 16 controls, with four controls only
providing a single spectrum.
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Subject ID

Clinical Seizure
Lateralization

Duration of
Epilepsy (Years)

Seizure Frequency
at Time of Scan

Observed Asymmetry in
Concentration Ratios
(Left Hippocampus)

Observed Asymmetry in
Absolute Concentration
(Left Hippocampus)

MRS Seizure
Lateralization from
Absolute Asymmetry

P01

Right

7

1-2 per mo.

-

[NAA], [Cr]

Indeterminate

P03

Left

4

1 per mo.

 Glx/Cr

[Glx]

Left

P08

Left

1

1 per mo.

-

 [Cr]

Left

P10

Right Origin
Seizures,
Bilateral Spikes

1

3 per yr.

 Cho/Cr,  Myo/Cr

[Cr], [Cho],
[Myo], [Glx]

Right

P12

Left

28

1 per mo.

-

-

-

P13

Right

1

30 per mo.

-

[Cho]

Right

P14

Left

5

Sz Free for 1 yr.

-

[Cr]

Right*

P15

Right

2

4 per mo.

-

[Cho]

Left*

P16

Bilateral

8

4 per mo.

-

[Cr], [Myo]

Right

P17

Bilateral

10

7 per mo.

-

-

-

P18

Right

1

17 per mo.

 NAA/Cr,  NAA/(Cr+ Cho)

-

-

P19

Right

2

Sz Free for 2 yr.

 Cho/Cr

[Cr], [Cho]

Left*

P21

Right

1

1 per yr.

-

-

-

P22

Right

1

7 per yr.

-

-

-

1

1 per yr.

-

-

-

P02

Unknown,
Bilateral Seizure
Spread
Right

2

1 per mo.

Only One Spectrum Collected

P04

Left

2

8 per mo.

Only One Spectrum Collected

P09

Bilateral

0.5

4 per yr.

Only One Spectrum Collected

P23

Bilateral

22

18 per mo.

Only One Spectrum Collected

P24

Table 2.1 – Patient Demographics and MRS Asymmetry Results – Clinical data and MRS results for all patients included in analysis;
starred entries in the rightmost column indicate incorrect MRS lateralization. Directionality of metabolite change is based on whether
concentration is increased () or decreased () in the left hippocampus relative to the right.
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2.2.2 Seizure Lateralization
Clinically established seizure lateralization was used in later analyses for
classification of MRS spectra. This was determined for each patient as part of
clinical treatment, primarily using interictal scalp EEG data and seizure
semiology. Additional clinical information such as ictal and/or intracranial
EEG was used for lateralization where available.
2.2.3 MR Protocol
Due to hardware and software upgrades performed on our 7T MR scanner,
two different MR protocols were used over the course of this study.
The first eight patients and eight healthy controls were scanned on a 7T
Agilent/Siemens head-only MRI system using a 16 channel transmit and
receive birdcage RF head coil (built in house). T1-weighted images were
collected using an MPRAGE sequence (TE = 2.22 ms, TR = 6.24 ms, voxel size
0.59x0.43x1.00 mm) after global shimming. These images were later used for
determining voxel placement. MRS data were acquired using a semi-LASER
sequence (TE = 37.5 ms, TR = 3700 ms, 256 averages) from a 2.7x1.3x1.3 cm3
voxel placed centrally over the hippocampus (See Figure 2.1, row A). This
sequence interleaved a water suppressed metabolite spectrum with a
metabolite nulled macromolecule spectrum [19], [20]. Metabolite nulling was
achieved using a double inversion recovery preparation incorporating two
non-selective 5ms adiabatic full passage (AFP) pulses to suppress metabolite
signal [18]. Data were obtained from two separate voxels positioned to
include the left and right hippocampi. From each voxel we acquired an
unsuppressed water spectrum as an internal reference signal for
quantification, a full spectrum containing all metabolite and macromolecule
resonances using VAPOR water suppression [21], and the previously
described macromolecule only spectrum.
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Figure 2.1 – Hippocampal Voxel Placement: Image showing voxel placement for A) TE =
37.5 ms acquisition overlaid on a 𝑇1 weighted MPRAGE image and B) a TE = 60 ms
acquisition overlaid on a 𝑇1 weighted MP2RAGE image. For the TE= 37.5 ms acquisition, the
MRS voxel was places along the cardinal axes of the MR system, whereas in the TE= 60 ms
acquisition the voxel was placed at an oblique angle such that it followed the length of the
hippocampus.
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The remaining participants were scanned on a 7T Siemens head-only MRI
system using a custom built head-only phased array composed of 8 transmit
and 32 receive channels. T1-weighted images were collected using an
MP2RAGE sequence (TE = 2.83 ms, TR = 8.3 ms, voxel size 0.75 mm
isotropic). MRS data were collected using a semi-LASER sequence (TE = 60,
TR = 7500, 64 averages) from a 2.7x1.3x1.3 cm3 voxel. This voxel was
positioned obliquely along the long axis of the hippocampus (Figure 2.1, row
B). From this voxel we acquired an unsuppressed water spectrum and a full
spectrum containing metabolite and macromolecule resonances using VAPOR
water suppression. This sequence did not incorporate an interleaved
macromolecule only acquisition.
2.2.4 Spectral Processing and Metabolite Quantification
Metabolite levels were measured using custom software developed by our lab.
All data first underwent a combination of QUALITY deconvolution, to restore
peak Lorentzian lineshape, and eddy current correction. Residual water
signals were removed by subtracting an automated Hankel singular value
decomposition fit of the water peaks from the acquired spectrum [22], [23].
Metabolite lineshapes were simulated for each pulse sequence using custom
software built with PyGamma [24], producing templates that were fitted to
the in vivo data [25]. The macromolecule only spectra acquired from the
healthy controls scanned with TE= 37.5 ms were averaged together to create
a template for fitting the macromolecule component. This macromolecule
lineshape was added to the prior knowledge templates for data acquired on
both MRI systems. The in vivo data were then fitted to the simulated
metabolite and macromolecule templates in the time domain using a
Levenberg-Marquard minimization algorithm to determine the contribution
of each metabolite to the in-vivo spectrum [23]. This fitting algorithm
established the best possible fit by adjusting peak amplitude for each
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metabolite, chemical shift and phase for 5 different groups of metabolites
(See Table 2.2), and total spectral linewidth. In total, 14 metabolites were
simulated and used to fit the in vivo spectrum; these were N-acetylaspartate
(NAA), N-acetylaspartate glutamate, total creatine (Cr), total choline (Cho),
lactate, myo-inositol (Myo), scyllo-inosotol, glutamate and glutamine
(combined into the measure Glx), glutathione, taurine, glucose, glycine,
phosphorylethanolamine, and 𝛾-aminobutyric acid. The concentration for
each metabolite was calculated both as a ratio to Cr, and as an absolute
concentration using the separately acquired water as an internal reference
signal. In addition, NAA/(Cr+ Cho) was calculated for comparison with
previous findings in the literature.
Ratios to Cr were calculated by summing the peak amplitudes contributing to
each metabolite lineshape, then dividing the normalized metabolite
amplitude with that of Cr (see Equation 2.1):

𝑋⁄𝐶𝑟 =

Σ𝑆𝐴𝑚𝑝,𝑋
Σ𝑆𝐴𝑚𝑝,𝐶𝑟

(2.1)

where 𝑋⁄𝐶𝑟 is the ratio of the metabolite of interest X to Cr, and Σ𝑆𝐴𝑚𝑝,𝑋 and
Σ𝑆𝐴𝑚𝑝,𝐶𝑟 are the total amplitude of all peaks that form the spectral line shape
of the metabolite of interest and Cr.
Absolute metabolite levels, which provide average metabolite concentrations
within the combined grey/white matter tissue fraction of voxel, were
evaluated using the following expression (Equation 2.2):

[𝑋] 𝑇𝑖𝑠𝑠𝑢𝑒 =

Σ𝑆𝐴𝑚𝑝,𝑋 𝑛𝜌,𝐻2 𝑂 𝑅𝐻2 𝑂
∗ [𝐻2 𝑂]𝑉𝑜𝑥𝑒𝑙 ∗ (𝐺𝑀 + 𝑊𝑀)
Σ𝑆𝐴𝑚𝑝,𝐻2 𝑂 𝑛𝜌,𝑋 𝑅𝑋

(2.2)

where [𝑋]𝑇𝑖𝑠𝑠𝑢𝑒 is the concentration of the metabolite of interest within the
tissue fraction of the MRS voxel, Σ𝑆𝐴𝑚𝑝,𝑋 and Σ𝑆𝐴𝑚𝑝,𝐻2 𝑂 are the sum of spectral
peak amplitudes for the metabolite of interest and water respectively, 𝑛𝜌,𝑋
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and 𝑛𝜌,𝐻2 𝑂 are the number of protons producing spectral signal for both the
metabolite of interest and water, 𝑅𝑋 and 𝑅𝐻2 𝑂 are corrections for the
combined 𝑇1 and 𝑇2 relaxation of both the metabolite of interest and water
(See Table 2.2), [𝐻2 𝑂]𝑉𝑜𝑥𝑒𝑙 is the average concentration of water within the
voxel (based on GM/WM/CSF tissue fractions), and (𝐺𝑀 + 𝑊𝑀) is the voxel
tissue fraction for grey and white matter [26].
In all cases, voxel tissue volume fractions were evaluated using the Oxford
Centre for Functional MRI of the Brain (FMRIB) software library (FSL) [27].
Images were brain extracted using FSL's Brain Extraction Tool (BET)[28],
while GM/ WM/ CSF voxel fractions were determined using the FMRIB
Automated Segmentation Tool (FAST) [29]. Literature reported relaxation
and water concentration values were used in Equation 2 (See Table 2.2) [30]–
[33].
2.2.5 Statistical Analysis
Metabolites were excluded from analysis if the coefficient of variation (CV) of
their absolute concentration within the healthy control group was greater
than 35%. This was done to exclude both metabolites that were not reliably
fit by the fitting algorithm, and to exclude metabolites with high variability
within a healthy population. The metabolites with CVs below this threshold
that were included in the subsequent group comparisons were NAA, Cho, Cr,
Myo, and Glx.
For group comparisons, both absolute and relative metabolite concentrations
were compared between healthy controls, data from patient hippocampi
ipsilateral to clinically established seizure focus, and data from patient
hippocampi contralateral to seizure focus. This was accomplished using a
pair of MANCOVA tests; one comparing absolute metabolite levels across
groups, and the other comparing metabolite ratios. In each test, two
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Chemical Shift and
Phase Group for Fit

T1 Grey
Matter (s)

T2 Grey
Matter (ms)

T1 White
Matter (s)

T2 White
Matter (ms)

N-Acetylaspartate

NAA

1.83 ±0.05

191 ± 7

1.90 ±0.06

164 ± 6

N-Acetylaspartyl
Glutamate

NAA

1.21 ± 0.22

191 ± 7

0.94 ± 0.08

164 ± 6

Lactate

NAA

1.28 ± 0.08

160 ± 20

1.19 ± 0.07

100 ± 15

Creatine (CH3)

Cr

1.74 ± 0.06

131 ± 8

1.78 ± 0.04

113 ± 2

Creatine (CH2+ NH)

Cr

1.13 ± 0.04

102 ± 3

1.10 ± 0.06

108 ± 5

Choline

Cho

1.51 ± 0.11

200 ± 17

1.32 ± 0.06

139 ± 9

Myo-inositol

Myo

1.28 ± 0.08

160 ± 20

1.19 ± 0.07

100 ± 15

Alanine

Myo

1.28 ± 0.08

160 ± 20

1.19 ± 0.07

100 ± 15

Assumed same relaxation times as Myo-inositol

Glucose

Myo

1.28 ± 0.08

160 ± 20

1.19 ± 0.07

100 ± 15

Assumed same relaxation times as Myo-inositol

Glycine

Myo

1.28 ± 0.08

160 ± 20

1.19 ± 0.07

100 ± 15

Assumed same relaxation times as Myo-inositol

Phosphorylethanolamine

Myo

1.31 ± 0.18

160 ± 20

1.32 ±0.30

100 ± 15

Scyllo-inositol

Myo

1.31 ± 0.20

130 ± 20

1.23 ± 0.07

112 ± 4

Taurine

Myo

2.15 ± 0.11

120 ± 20

2.09 ± 0.04

90 ± 16

Glutamate

Glu

1.61 ± 0.09

139 ± 8

1.75 ± 0.04

98 ± 4

Glutamine

Glu

1.64 ± 0.07

139 ± 8

1.74 ± 0.23

98 ± 4

Glutathione

Glu

1.14 ± 0.18

80 ± 10

1.06 ± 0.06

97 ± 8

GABA

Glu

1.33 ± 0.16

87 ± 11

1.33 ± 0.16

87 ± 11

Andreychenko et. Al. (2013)

Water

Fit in separate
water spectrum

2.00 ± 0.12

48 ± 3

1.55 ± 0.07

47 ± 1

T1 values from Marjanska et. Al. (2012); T2 values from Xin et. Al.
(2013)

Metabolite

Source
T1 values from Marjanska et. Al. (2012); T2 values from Xin et. Al.
(2013)
T1 values from Marjanska et. Al. (2012); T2 assumed to be the
same as N-Acetylaspartate
Assumed same relaxation times as Myo-inositol
T1 values from Marjanska et. Al. (2012); T2 values from Xin et. Al.
(2013)
T1 values from Marjanska et. Al. (2012); T2 values from Xin et. Al.
(2013)
T1 values from Marjanska et. Al. (2012); T2 values from Xin et. Al.
(2013)
T1 values from Marjanska et. Al. (2012); T2 values from Xin et. Al.
(2013)

T1 values from Marjanska et. Al. (2012); T2 assumed to be the
same as Myo-inositol
T1 values from Marjanska et. Al. (2012); T2 values from Xin et. Al.
(2013)
T1 values from Marjanska et. Al. (2012); T2 values from Xin et. Al.
(2013)
T1 values from Marjanska et. Al. (2012); T2 values from Xin et. Al.
(2013)
T1 values from Marjanska et. Al. (2012), T2 assumed to be the
same as Glutamate
T1 values from Marjanska et. Al. (2012); T2 values from Xin et. Al.
(2013)

Table 2.2 – Metabolite Shift Groupings and 7T Relaxation Times used for Absolute Metabolite Quantification

62
covariates were used to correct for differences between pulse sequences; one
was a categorical variable indicating which system was used to collect the
data, and the other was voxel white matter content. White matter content
was specifically added tot his analysis due to a significant difference in the
white matter content between the different voxels used. Statistical analysis
was performed in SPSS Statistics (IBM, version 25, 2017).
To determine whether individual metabolites were associated with seizure
lateralization, asymmetry indices were calculated for both metabolite ratios
and absolute concentrations (Equation 2.3):

𝐴𝐼 =

[𝑋]𝐿𝑒𝑓𝑡 − [𝑋]𝑅𝑖𝑔ℎ𝑡
([𝑋]𝐿𝑒𝑓𝑡 + [𝑋]𝑅𝑖𝑔ℎ𝑡 )/2

(2.3)

where AI is the asymmetry index, and [𝑋]𝐿𝑒𝑓𝑡 and [𝑋]𝑅𝑖𝑔ℎ𝑡 are the
concentrations of the metabolite of interest in the left and right hippocampi
respectively [34]. To assess abnormality, the average AI and its standard
deviation were calculated for the healthy control group. Patients were said to
have abnormal asymmetry if their asymmetry index for a metabolite fell
more than two standard deviations away from the control average. Seizure
lateralization was made based on these observed asymmetry abnormalities,
and the expected metabolite changes reported in the literature (ipsilaterally,
NAA level was expected to decrease, Cho and Cr levels were expected to
increase). Asymmetry indices that fell within two standard deviations of the
control average were considered non-lateralizing. Average absolute z-scores
were calculated to establish the mean absolute difference in asymmetry
between patients and healthy controls.
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2.3 Results
2.3.1 Group Analysis
A typical spectrum acquired from the hippocampus of one participant is
provided in Figure 1.6 (pg. 29) along with the fitted metabolite components.
In comparison to the primary NAA peak, MRS spectra had an average SNR=
25.8± 8.2, while the average linewidth of the unsuppressed water peak was
16.8± 3.4 Hz. The average GM/WM/CSF fractions within hippocampal voxels
were 58± 11%/36± 13%/5± 4% for the TE=37.5 ms data and 65± 5%/25±
7%/10± 4% for the TE=60 ms data. Average metabolite levels and ratios for
control hippocampi, patient contralateral hippocampi, and patient ipsilateral
hippocampi are provided in Table 2.3. For patients with bilateral TLE, both
hippocampi were included in the ipsilateral group. When comparing healthy
controls to ipsilateral hippocampi to contralateral hippocampi, the
MANCOVA analysis showed a significant increase in [Cho] when comparing
ipsilateral hippocampi to controls (p = 0.03). The MANCOVA did identify and
correct for significant differences in the measured concentrations between the
TE=37.5 and TE=60 ms pulse sequences; [NAA] was 20% higher in the TE=
60 ms data, [Cho] was 17% lower in the TE= 60 ms data, [Glx] was 45%
higher, NAA/Cr was 41% higher, Myo/Cr was 22% higher, Glx/Cr was 58%
higher, and NAA/(Cr+Cho) was 40% higher.
2.3.2 Asymmetry Analysis
The results of the asymmetry analysis are summarized in Table 2.4. In
patients, there was a high level of asymmetry (average |𝑧|= 1.76) in the
absolute concentration of Cr in patients compared to healthy controls. When
used to lateralize seizure focus, [Cr] increase correctly lateralized seizure
focus in 3/12 patients with unilateral seizure focus while also meeting our
abnormality criterion of >2 SD from healthy control mean in 1/3 patients
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Measure

Control
Average and
Standard
Deviation

Contralateral
Patient Average
and Standard
Deviation

Ipsilateral Patient
Average and
Standard
Deviation

Group
Difference
f-statistic

Group
Difference
p-value

N-Acetylaspartate (mM)

11.4 ± 1.9

11.6 ± 3.0

11.5 ± 2.1

0.45

0.64

Creatine (mM)

11.6 ± 1.5

11.9 ± 2.9

11.7 ± 2.5

1.84

0.17

Choline (mM)

3.4 ± 0.5

3.5 ± 0.8

3.9 ± 1.0

3.60

0.03*

Myo-inositol (mM)

6.7 ± 1.4

6.2 ± 2.2

6.8 ± 3.0

0.17

0.84

Glx (mM)

9.8 ± 3.0

8.8 ± 5.9

9.2 ± 4.1

0.06

0.94

NAA/Cr

1.08 ± 0.29

1.03 ± 0.31

1.06 ± 0.38

0.18

0.84

Cho/Cr

0.96 ± 0.13

0.92 ± 0.09

1.00 ± 0.24

1.90

0.16

Myo/Cr

0.80 ± 0.18

0.71 ± 0.24

0.82 ± 0.35

0.90

0.41

Glx/Cr

0.84 ± 0.34

0.77 ± 0.47

0.82 ± 0.46

0.46

0.63

NAA/(Cho+ Cr)

0.55 ± 0.14

0.53 ± 0.15

0.53 ± 0.17

0.39

0.68

Table 2.3 – Metabolite Levels Within Subject Groups and p-values from MANCOVA Analysis: Average values are given without
any corrections for co-varying factors, p-values given by main MANCOVA analyses

65

Measure

Control
Asymmetry
Average Score

Controls Outside
2 Standard
Deviations

Patients with
Ipsilat. Increase
(>2 SD)

Patients with
Ipsilat. Decrease
(>2 SD)

Average Patient
Absolute Z-Score

N-Acetylaspartate (mM)

-0.03 ± 0.22

1

1

0

0.79

Creatine (mM)

0.16 ± 0.15

0

4

2

1.76

Choline (mM)

0.15 ± 0.15

1

2

1

1.16

Myo-inositol (mM)

0.20 ± 0.42

1

2

1

1.03

Glx (mM)

0.35 ± 0.58

1

2

0

0.72

NAA/Cr

-0.20 ±0.23

1

0

1

0.72

Cho/Cr

-0.04 ±0.18

1

1

1

0.87

Myo/Cr

-0.01 ± 0.40

1

1

0

0.80

Glx/Cr

0.23 ± 0.52

0

1

0

0.77

NAA/(Cr+ Cho)

-0.18 ± 0.21

1

0

1

0.83

Table 2.4 – Average Metabolite Asymmetry Scores and Lateralization Results
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with bilateral TLE (Table 2.1). The other metabolic metrics calculated had
lower absolute z-scores and were not as successful at lateralizing seizure
origin. For each of these measures, anomalous asymmetry only lateralized
one or two of the unilateral patients.
When lateralizing seizure focus using all observed metabolic change in a
given subject, metabolite asymmetries successfully lateralized 4/12 unilateral
TLE patients, with 3 incorrect lateralizations, and one indeterminate result.
For the 4 bilateral TLE patients examined in this analysis, metabolite
asymmetry gave an indeterminate result for one patient, and lateralized
seizure focus to the right temporal lobe for another.
2.4 Discussion
In this study of non-lesional TLE, we identified a significant increase in the
absolute level of Cho in ipsilateral hippocampi from non-lesional TLE
patients compared to healthy controls. On an individual basis we found
substantial variation in [Cr], which successfully lateralized 3/16 patients
using our lateralization criteria of being more than two standard deviations
from the mean control level. When corrected for the differences between pulse
sequences, we found a significant change in [Cho] levels between groups.
Comparing the mean values for [Cho], we see that there is an increase in
[Cho] levels ipsilateral to seizure focus relative to control measurements. In
the existing literature, changes in Cho have not been previously reported in
non-lesional TLE. Increases in choline are associated with cellular membrane
turnover, cell density, and gliosis [35], [36]; in studies of epilepsy Cho is
commonly included in ratio quantities such as NAA/(Cho+Cr) to sensitize
these metrics to increased gliosis, and choline changes have been previously
reported by studies examining lesional TLE [2], [6], [10], [37]–[39]. The most
common histological finding in MRI-normal TLE is nonspecific gliosis without
neuronal damage or loss [2], [7]. With this in mind, our observed changes in
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Cho appear to be in agreement with the existing literature, as the known
prevalence on gliosis within this patient group is most likely to result in Cho
increases [2], [39]. Meanwhile our results did not show a change in NAA
levels, the most commonly reported change in the epileptic population [40],
[41]. NAA change is typically associated with neuronal dysfunction or loss
[18], [36], [42]. As this patient group histologically does not consistently show
neuronal damage as in other epilepsies [2], [7], our lack of significant NAA
change appears to be consistent with previous research.
The observed variation of [Cr] is also noteworthy. Prior studies have reported
metabolite levels as ratios to Cr either due to its assumed invariance between
healthy and seizure forming tissue [36], or as a proposed functional measure
where a combination of decreases in NAA and increases in Cr created a more
powerful measure than the individual metabolites [39], [43]. Our results
indicate that in non-lesional TLE absolute [Cr] and [Cho] levels may be more
useful than metabolite ratios. While we do not see a consistent ipsilateral
change in [Cr] levels between healthy and epileptic tissue, we do see
substantial variation in [Cr] levels within patients that is not present in
healthy controls. More concerning, this variance in Cr may mask significant
changes in other metabolites; we found significant changes in absolute [Cho]
levels in our group analysis, however this change was not observed in the
Cho/Cr ratio.
One potential factor accounting for the large variance of [Cr] without
significant changes in the group analysis is the MRI-negative nature of the
patient population. Given the lack of identifiable MRI changes and any
histological information, the underlying pathology causing seizures in each
patient is unknown. Histology has shown that MRI negative TLE is a
heterogeneous group in terms of pathology [2]. It therefore follows that our
patient population is heterogeneous in terms of underlying pathology and as
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such we would expect patients to have differing metabolic abnormalities.
When grouped together, these differing metabolic profiles could very easily
average out to no significance, leading to our observed variations in [Cr].
Spectroscopy data for this study were acquired using two different parameter
sets for the semi-LASER sequence. Pulse sequence specific simulations were
used to account for differences in the metabolite lineshapes arising from
differences in echo times. In the MANCOVA analysis, significant differences
attributable to the pulse sequences used were found in [NAA], [Cho], [Glx],
NAA/Cr, Myo/Cr, Glx/Cr, NAA/(Cr+Cho). These changes can be partially
explained by the differing tissue fractions within the different voxels used.
The concentrations calculated in our analysis are the average concentration
of metabolites within the tissue component of our voxel, as CSF contains
negligible metabolite levels, yet the concentration of various metabolites
change between grey and white matter. Between our two pulse sequences,
62% of the signal collected during the TE= 37.5 ms acquisition is from grey
matter versus a grey matter contribution of 72% for the TE= 60 ms
acquisition, with white matter contributing the remaining signal in both
cases. NAA, Glu, Myo, and Cr all are present in higher concentrations in grey
matter than white matter [18], [36], [44], while Cho levels are higher in white
matter than cortical grey matter [45]. These results match with the
variations identified by our MANCOVA analysis, where Cho is lower and
other metabolites are higher in the TE=60 ms acquisition, with its higher
grey matter component.
Several other factors were not controlled for in this study. No corrections
were made for the potential impact of anti-epileptic drugs on the MRS
results. In addition, time since last seizure at time of scan was not tracked.
Seizures have been shown to temporarily cause substantial variation in
metabolite levels immediately post-seizure which persist for several hours
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post-ictally, making time from last seizure a complicating factor, particularly
when examining patients with frequent seizures [46].
2.5 Conclusion
From our analysis, it appears that choline and creatine, as measured
independently from one another as absolute quantities, may be biomarkers
for epileptic tissue in non-lesional TLE patients. While our results are in
general agreement with the existing literature, additional and larger studies,
ideally incorporating histological data when available, are necessary to
establish the clinical utility of these measures.
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3.1 Conclusions
In this thesis, we aimed to detect metabolite level changes in epileptic tissue
using high field magnetic resonance spectroscopy (MRS) in non-lesional TLE
patients. To this end, we performed the first single-voxel MRS measurements
at a magnetic field strength of 7T in this cohort.
We found that average absolute choline and creatine concentrations were
altered in non-lesional TLE patients compared to healthy controls. Similar
variations were not found in the commonly used measures NAA/Cr and
NAA/(Cr + Cho). The demonstrated alterations were consistent with preexisting knowledge about non-lesional TLE, suggesting these two metabolites
were noteworthy candidates for future metabolic imaging studies. However,
levels of these metabolites were not sufficiently different to be useful in
seizure lateralization.
There are two primary factors that could be contributing to this poor
lateralization ability. Firstly, due to the MRI-normal nature of this patient
population we do not have a clear picture of the underlying pathology;
differing pathologies would have different metabolic effects, causing the
significant but inconsistent changes seen in our results. Furthermore, there
is likely a combination of healthy and epileptogenic tissue within our chosen
voxel, in varying amounts in each patient. Given that concentration is
measured as an average in all the tissue in a voxel, this would dilute any
metabolic asymmetries our chosen measurement technique could identify in
these patients. Lowering our criteria for determining significant asymmetry
could help correct for this partial volume effect. However, lowering the
significance threshold also increases the risk that non-pathologic variances in
metabolite levels, created either by normal variance in metabolite levels, or
by variance in the grey matter/white matter composition of our voxel, would
give incorrect seizure lateralization. Another noteworthy confounding factor

77
for Cho in particular in this regard is diet; Cho levels within the brain are
sensitive to the Cho content of food eaten and time since last meal, and
dietary Cho fluctuations could be obscuring Cho changes due to epilepsy [1].
In this thesis, we had hoped to demonstrate the clinical utility of 7T MRS.
While our conclusions were complicated by changes in scanner hardware and
software over the course of our study, based on the data obtained in this
study, it does not appears that 7T MRS of the hippocampus in TLE patients
provides effective seizure lateralization in the majority of patients. The
metabolic changes we detected occurred in metabolites that are readily
identifiable at lower field strength. With that said, 7T systems have
demonstrated advantages in identifying small lesions in ‘non-lesional’
epilepsy cases [2], and they may have an advantage when performing MRSI
or other metabolic imaging techniques which were beyond the scope of this
thesis.
3.2 Future Work
The work presented in this thesis could be meaningfully expanded in a
number of different ways.
The significant variations in metabolite levels did not provide good
lateralization ability in our study. To clearly identify if [Cho] and [Cr] levels
are clinically useful in seizure localization, the various confounding factors
discussed above should be addressed. To avoid the specificity issues noted
with a single voxel measurement, MRSI or other metabolic imaging
measurements studying the behaviour of these metabolites as absolute
concentrations are needed, as none currently exist in the literature.
Performing such studies at a field strength of 7T could provide the spectral
and spatial resolution needed to identify small epileptic foci which elude
accurate characterization by single voxel techniques. Ideally, such studies
would be paired whenever possible with histopathology of the underlying
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tissue, to more clearly identify which metabolites are affected under differing
pathologies.
A number of animal studies have shown that Cho dietary supplementation
has a neuroprotective effect in rodent models of epilepsy [3]. In light of the
Cho changes we have identified, a rodent study that uses MRS to study Cho
level change in rodents pre- and post-epileptogenesis with differing levels of
dietary Cho could provide useful information on the behaviour of Cho in
epilepsy. We found no studies examining the effects of dietary Cho
supplementation in the human epileptic population. While a human study
examining the effects of dietary choline would be challenging to carry out, if
Cho has the same neuroprotective effect in humans as seen in animal models,
it could be used to improve the quality of life of intractable epilepsy patients
by reducing the cognitive decline seen in these patients.
In the existing literature on epilepsy, very few studies examine the dynamic
changes in MRS metabolite levels; the only study found in our review of the
literature examining this was a small study of 5 patients [4]. Establishing the
clinical utility of MRS requires that any variation in metabolite levels are
known and can be controlled for, thus more and larger studies examining
post-ictal metabolite changes are needed.
This leads into a common problem with epilepsy studies as a whole; the
general lack of large scale, multi-centre studies makes it difficult to
demonstrate the clinical utility of MRS in epilepsy. Given that dozens of
smaller scale studies conducted over 3 decades have demonstrated that there
are metabolic changes occurring in the epileptic population, and that
metabolic changes are associated with seizure focus, such a study could
provide a powerful case for clinical use of MRS techniques.
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